Press |

Circulerende tumorcellen bij mCRPC patienten

De uitkomsten van een biomarker studie bij mCRPC uitgevoerd in diverse DUOS ziekenhuizen staat sinds kort online in de augustus editie van Cancers.

Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel

Conclusion: These data show that characterization of CTCs as of yet did not hold sufficient power to distinguish outcome to cabazitaxel treatment. However, our data confirms the strong, independent prognostic value of the CTCs for both PFS and OS in mCRPC patients that are treated with cabazitaxel in the second line, together with alkaline phosphatase and hemoglobin.

Meer op DUOS

© 2019, Stichting DUOS, redactie en teksten: Kuip&Ko, website: sbddesign.nldisclaimer   |   log in